Literature DB >> 22753919

Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies.

John L Marshall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22753919     DOI： 10.1200/JCO.2012.43.4233

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Tumor microenvironment and nanotherapeutics.

Authors:  Meenakshi Upreti; Amar Jyoti; Pallavi Sethi
Journal:  Transl Cancer Res       Date:  2013-08-01       Impact factor: 1.241

2.  Encapsulation of Anticancer Drugs (5-Fluorouracil and Paclitaxel) into Polycaprolactone (PCL) Nanofibers and In Vitro Testing for Sustained and Targeted Therapy.

Authors:  Sakib Iqbal; Mohammad H Rashid; Ali S Arbab; Mujibur Khan
Journal:  J Biomed Nanotechnol       Date:  2017-04       Impact factor: 4.099

3.  Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle.

Authors:  Marc P Kai; Amanda W Keeler; Jillian L Perry; Kevin G Reuter; J Christopher Luft; Sara K O'Neal; William C Zamboni; Joseph M DeSimone
Journal:  J Control Release       Date:  2015-03-03       Impact factor: 9.776

Review 4.  Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.

Authors:  Devron R Shah; Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

Review 5.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

Review 6.  Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.

Authors:  Hua Fang; Yves A Declerck
Journal:  Cancer Res       Date:  2013-08-02       Impact factor: 12.701

7.  Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.

Authors:  Suyoun Chung; Kyoko Kijima; Aiko Kudo; Yoshiko Fujisawa; Yosuke Harada; Akiko Taira; Naofumi Takamatsu; Takashi Miyamoto; Yo Matsuo; Yusuke Nakamura
Journal:  Oncotarget       Date:  2016-04-05

8.  An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.

Authors:  Amar Jyoti; Kyle D Fugit; Pallavi Sethi; Ronald C McGarry; Bradley D Anderson; Meenakshi Upreti
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

9.  A Computational Approach for Identifying Synergistic Drug Combinations.

Authors:  Kaitlyn M Gayvert; Omar Aly; James Platt; Marcus W Bosenberg; David F Stern; Olivier Elemento
Journal:  PLoS Comput Biol       Date:  2017-01-13       Impact factor: 4.475

Review 10.  A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab.

Authors:  Lucinda Villaescusa; Francisco Zaragozá; Irene Gayo-Abeleira; Cristina Zaragozá
Journal:  Adv Ther       Date:  2022-01-24       Impact factor: 3.845
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.